Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM

Phase 1 Unknown 60 enrolled CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of mitoxantrone hydrochloride liposome injection in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma.

Timeline

Start: 2021-10-20
Primary completion: 2023-04-20
Completion: 2024-06-20

Publications

Zhou YL, Zhang JQ, Wang W, Bao L, Fang BJ, Gao D, Su LP, Chen WM, Yang GZ. Bortezomib, Mitoxantrone Hydrochloride Liposome, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Multi-Center, Open-Label Phase I Trial. Cancer Med. 2025 Apr;14(8):e70890. doi: 10.1002/cam4.70890.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Mitoxantrone	Small molecule	12 mg/m2	Intravenous
Subject	Mitoxantrone	Small molecule	16 mg/m2	Intravenous
Subject	Mitoxantrone	Small molecule	20 mg/m2	Intravenous
Background	Bortezomib	Small molecule	1.3 mg/m2	Intravenous
Background	Dexamethasone	Small molecule	20 mg	Oral

Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM

Summary

Timeline

Publications

Drugs

Indications